MCM
CATX icon

Massar Capital Management’s Perspective Therapeutics CATX Stock Holding History

Massar Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,000
Closed -$143K – 267
2025
Q4 		$143K Buy
+52,000
New +$148K 0.02% 311

Other funds holding CATX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massar Capital Management's CATX Position: Q1 2026 in Review

Massar Capital Management sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 52,000 shares — an estimated $143K sold.

Massar Capital Management first reported a position in CATX in Q4 2025 and held it in 1 quarter. The position peaked at $143K in Q4 2025. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Massar Capital Management reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Massar Capital Management sold 52,000 Perspective Therapeutics shares in Q1 2026, an estimated $143K.
  • Massar Capital Management first reported a position in Perspective Therapeutics in Q4 2025 and held it in 1 quarter.
  • Massar Capital Management's Perspective Therapeutics position peaked at $143K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Massar Capital Management's 13F filing for Q1 2026, filed 15 May 2026.